Recent	JJ
advances	NNS
in	IN
molecular	JJ
targets	NNS
and	CC
treatment	NN
of	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
:	:
focus	VB
on	IN
TGFbeta	NN
signaling	NN
and	CC
the	DT
myofibroblast	NN
.	.

Idiopathic	JJ
Pulmonary	JJ
Fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
characterized	VBN
by	IN
injury	NN
and	CC
loss	NN
of	IN
lung	NN
epithelial	JJ
cells	NNS
,	,
accumulation	NN
of	IN
fibroblasts/myofibroblasts	NNS
and	CC
abnormal	JJ
remodeling	NN
of	IN
the	DT
lung	NN
parenchyma	NN
.	.

The	DT
prognosis	NN
for	IN
IPF	NN
patients	NNS
is	VBZ
poor	JJ
and	CC
current	JJ
therapies	NNS
are	VBP
largely	RB
ineffective	JJ
in	IN
preventing	VBG
respiratory	JJ
failure	NN
.	.

Current	JJ
therapeutic	JJ
approaches	NNS
target	VBP
epithelial	JJ
cell	NN
replacement	NN
,	,
manipulation	NN
of	IN
fibroblasts/myofibroblasts	NNS
,	,
modulation	NN
of	IN
procoagulant/fibrinolytic	JJ
activities	NNS
,	,
cytokine	NN
and	CC
growth	NN
factor	NN
production	NN
,	,
angiogenesis	NN
,	,
and	CC
reduction	NN
of	IN
oxidative	JJ
stress	NN
.	.

Myofibroblasts	NNS
are	VBP
the	DT
primary	JJ
effector	NN
cells	NNS
in	IN
fibrosis	NN
.	.

These	DT
cells	NNS
may	MD
be	VB
derived	VBN
by	IN
the	DT
activation	NN
and	CC
proliferation	NN
of	IN
resident	JJ
lung	NN
fibroblasts	NNS
,	,
from	IN
epithelial-mesenchymal	JJ
transition	NN
(	(
EMT	NN
)	)
,	,
or	CC
through	IN
recruitment	NN
of	IN
circulating	VBG
fibrocytes	NNS
.	.

Transforming-growth-factor-beta	NN
(	(
TGFbeta	NN
)	)
is	VBZ
a	DT
profibrotic	JJ
factor	NN
that	WDT
increases	VBZ
fibroblast	NN
proliferation	NN
,	,
stimulates	VBZ
the	DT
synthesis	NN
and	CC
deposition	NN
of	IN
connective	JJ
tissue	NN
,	,
and	CC
inhibits	VBZ
connective	JJ
tissue	NN
breakdown	NN
.	.

TGFbeta	NN
acts	VBZ
through	IN
the	DT
promoter	NN
of	IN
the	DT
type	NN
1	CD
collagen	NN
gene	NN
causing	VBG
increased	VBN
collagen	NN
synthesis	NN
.	.

In	IN
addition	NN
,	,
TGFbeta	NN
induces	VBZ
EMT	NNP
in	IN
alveolar	JJ
epithelial	JJ
cells	NNS
(	(
AECs	NNS
)	)
in	FW
vitro	FW
and	CC
in	FW
vivo	FW
.	.

AECs	NNS
exhibit	VBP
substantial	JJ
plasticity	NN
and	CC
may	MD
serve	VB
as	IN
a	DT
source	NN
of	IN
fibroblasts	NNS
and/or	CC
myofibroblasts	NNS
in	IN
lung	NN
fibrosis	NN
.	.

Therapeutic	JJ
interventions	NNS
interfering	VBG
with	IN
the	DT
pathways	NNS
that	WDT
lead	VBP
to	TO
myofibroblast	JJ
expansion	NN
and	CC
AEC	NN
apoptosis	NN
should	MD
be	VB
of	IN
considerable	JJ
benefit	NN
in	IN
the	DT
treatment	NN
of	IN
IPF	NN
.	.

This	DT
review	NN
will	MD
focus	VB
on	IN
the	DT
critical	JJ
role	NN
of	IN
TGFbeta	NN
on	IN
AECs	NNS
EMT	NN
and	CC
myofibroblasts	NNS
in	IN
the	DT
development	NN
of	IN
fibrosis	NN
.	.

